KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Sales: 2010-2025

Historic Return on Sales for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to -1.81%.

  • Nektar Therapeutics' Return on Sales changed negligibly% to -1.81% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.81%, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of -1.21% for FY2024, which is 185.00% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Return on Sales is -1.81%, which was down 17.56% from -1.54% recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Return on Sales peaked at -1.21% during Q4 2024, and registered a low of -5.46% during Q2 2022.
  • For the 3-year period, Nektar Therapeutics' Return on Sales averaged around -2.41%, with its median value being -1.90% (2024).
  • As far as peak fluctuations go, Nektar Therapeutics' Return on Sales tumbled by 225bps in 2021, and later spiked by 280bps in 2024.
  • Nektar Therapeutics' Return on Sales (Quarterly) stood at -5.15% in 2021, then soared by 108bps to -4.07% in 2022, then surged by 101bps to -3.06% in 2023, then soared by 185bps to -1.21% in 2024, then remained steady at -1.81% in 2025.
  • Its Return on Sales stands at -1.81% for Q3 2025, versus -1.54% for Q2 2025 and -1.47% for Q1 2025.